KIORA PHARMACEUTICALS, INC. Accretion (Amortization) of Discounts and Premiums, Investments
KIORA PHARMACEUTICALS, INC. (KPRX) reported Accretion (Amortization) of Discounts and Premiums, Investments of $8.03 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Cash Flow › Operating Activities
us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments · last filed 2026-08-07
- KIORA PHARMACEUTICALS, INC. accretion (amortization) of discounts and premiums, investments for the quarter ending 2024-12-31 was $77.02K.
- KIORA PHARMACEUTICALS, INC. accretion (amortization) of discounts and premiums, investments for the quarter ending 2024-09-30 was $117.95K.
- KIORA PHARMACEUTICALS, INC. accretion (amortization) of discounts and premiums, investments for the quarter ending 2023-12-31 was $0.00.
- KIORA PHARMACEUTICALS, INC. accretion (amortization) of discounts and premiums, investments for the quarter ending 2023-09-30 was $0.00.
- KIORA PHARMACEUTICALS, INC. accretion (amortization) of discounts and premiums, investments for fiscal 2025 was $112.31K, a 60.38% decline from fiscal 2024.
- KIORA PHARMACEUTICALS, INC. accretion (amortization) of discounts and premiums, investments for fiscal 2024 was $283.47K.
- KIORA PHARMACEUTICALS, INC. accretion (amortization) of discounts and premiums, investments for fiscal 2023 was $0.00.
| Period end | Accretion (Amortization) of Discounts and Premiums, Investments 3 month | Accretion (Amortization) of Discounts and Premiums, Investments 6 month | Accretion (Amortization) of Discounts and Premiums, Investments 9 month | Accretion (Amortization) of Discounts and Premiums, Investments 12 month |
|---|---|---|---|---|
| 2026-06-30 | $8.03K 10-Q · filed 2026-08-07 | |||
| 2025-12-31 | $112.31K 10-K · filed 2026-03-25 | |||
| 2025-06-30 | $98.42K 10-Q · filed 2026-08-07 | |||
| 2024-12-31 | $77.02K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $194.97K derived: sum of 2 quarters · filed 2026-03-25 | $283.47K 10-K · filed 2026-03-25 | |
| 2024-09-30 | $117.95K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-08 | $206.46K 10-Q · filed 2024-11-08 | ||
| 2024-06-30 | $88.50K 10-Q · filed 2024-08-09 | |||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-25 | $0.00 derived: sum of 2 quarters · filed 2025-03-25 | $0.00 10-K · filed 2025-03-25 | |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-08 | $0.00 10-Q · filed 2024-11-08 | ||
| 2023-06-30 | $0.00 10-Q · filed 2024-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |